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Available online 9 January 2016The inﬂammatory response is one of the ﬁrst defenses our body has to ﬁght against potential endangerments. It
plays a critical role in host defense, clearing and slowing the infection in the case of microbial invasion. During an
inﬂammatory response, a variety of cytokines are produced by cells and trigger or enhance the speciﬁc inﬂamma-
tion response. TNFα, one of these factors, plays a crucial role inmany immune and inﬂammatory processes, such
as proliferation, apoptosis, necrosis, and cell survival. It acts in orchestrating the cytokine cascade and the major
regulator of inﬂammatory cytokine production. Abnormality of TNFα signaling leads tomany diseases, including
rheumatoid arthritis, psoriasis, Crohn's disease, atherosclerosis, and cancer. Due to the importance of TNFα, reg-
ulating TNFα activity is a key to treat the related diseases. There is a long history of usingmedicinal herbs to treat
diseases related to inﬂammation.We searched for an ingredient that has the ability to inhibit TNFα, we examined
AOherbal extract, containing 10 individual herbs andmost of these herbs have anti-inﬂammatory activitywithin
humans. We have tested the anti-inﬂammatory ability of AO herbal extract onmice. Furthermore, we usedmac-
rophage cell from young mice and found that AO extract has the ability to reduce the inﬂammation by inhibiting
TNFα level.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Medicinal herb1. Introduction
The inﬂammatory response is one of the ﬁrst defenses the body has to
ﬁght against potential endangerments, such as infections and injury. It is
triggered by innate immune receptors that recognize damaged cells and
contaminant pathogens (Matzinger, 2002; Nathan, 2002; Medzhitov,
2008; Ashley et al., 2012). During an inﬂammatory response, a variety
of cytokines are produced by cells and trigger or enhance the speciﬁc in-
ﬂammatory response. Therefore, ﬁnding the inhibitors which are able to
block the inﬂammatory cytokines becomes the key path to blocking the
inﬂammation. Among these cytokines, the pro-inﬂammation factor
TNFα plays a crucial role in many immune and inﬂammatory processes,
such as proliferation, apoptosis, necrosis, and cell survival (Feldmann
et al., 1996; Keystone andWare, 2010. It acts in orchestrating the cytokine
cascade and the major regulator of inﬂammatory cytokine production.
Abnormality of TNFα signaling leads tomany diseases, including rheuma-
toid arthritis, psoriasis, Crohn's disease, and atherosclerosis. It is also asso-
ciated with sepsis, diabetes, and obesity. Due to the importance of TNFα,
regulating its activity becomes the major strategy in the treatment of
inﬂammation-related diseases. TNFα antibody drugs, such as etanercept,
inﬂiximab, adalimumab, certolizumab, and golimumab are proven toter, University of Louisville, CTR
. This is an open access article underbe the effective biological treatments for these diseases. However,
remission, relapse, and infection are the major reasons that we need bet-
ter treatments for these diseases (Feldmann et al., 1996; Tracey et al.,
2008; Keystone, 2011; Schett, 2011). In addition, the high cost of making
bio-product is another barrier. Therefore, researchers from pharmaceuti-
cal industries and academia have searched intensively to ﬁnd the small
molecular compoundswhich inhibit TNFα. However, due to the complic-
ity of TNFα functions, no one has had the success in ﬁnding a TNFα-spe-
ciﬁc small molecule inhibitor.
Herbal medicine has been used by many different cultures through-
out the world to treat illness. They use medicinal plant seeds, roots,
leaves, bark, as well as ﬂowers. Some herbs are used on their own and
are able to treat certain diseases; however, some herbs need to be
used in combination in order to be more effective. Herbal remedies
have been used long before recorded human history. Ancient Chinese
and Egyptian documents (papyrus) have recorded the use of herbal
remedies as early as 3000 BC (Zhu and Woerdenbag, 1995; Cheung,
2011; Tian, 2011). Other cultures including the Middle Eastern,
European, African, and Native American societies have also used herbs
for treatment (Zhu and Woerdenbag, 1995; Adams et al., 2012). In the
early 19th century, when chemical analysis and chemical synthesis
ﬁrst became available, scientists began to extract and modify the active
ingredients from plants. The conventional medicine which uses chemi-
cal drugs becamemoremainstream, and the use of herbalmedicines de-
clined (Zhu and Woerdenbag, 1995; Stone, 2008; Xu, 2011).the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. TNFα inhibition by AO herbal mixture. Left lane, WGP induction. Middle lane, AO
herbal extract was added after WPG induction. Right lane, solvent DMSO was added
after WGP induction.
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tes, etc., are still lacking an efﬁcient treatment, due to the extremely
complex and large amount of factors involved in the inﬂammatory sig-
nalingnetwork. Herbalmedicines have the special advantage, especially
those containing a combination of severalmedicinal herbs thatmight be
able to regulate multiple targets in the same time and become a poten-
tial candidate of treatment for these diseases. In this report, we demon-
strate that an herbal extract AO, containing 10 medicinal herbs, has the
ability to inhibit the pro-inﬂammatory factor TNFα activity by macro-
phage cells. Furthermore, we present evidence by in vivo mouse ear
edema inﬂammation assay. These preliminary studies not only con-
ﬁrmed that the AO herbal extract is able to reduce the inﬂammation
both in vivo and in vitro, but the assays and results will also be used as
standards for further compound identiﬁcation and characterization.
2. Experimental procedures
2.1. Materials
AO herbal extract was generously provided by Alpha Oasis LLC,
based on 10 individual herbs, including Japanese creeper, Chinese
honeylocust spine, extract of wooly datchmanspipe herb, root of
pubescent angelica, garden balsam stem, Cantonese buttercup, giant
typhonium tuber, euphorbia, semen hyoscyami, and sesame oil.
2.2. Culture macrophage cells
IACUC number: 13062.
To obtain the resident peritoneal macrophages, 6- to 8-week-old
mice were sacriﬁced and their peritoneal cavities were washed three
times with DEME supplemented with 10% FBS. The macrophages were
cultured in the 24-well tissue culture plates at 0.2 × 106 cells per well.
After incubating the cells at 37 °C for 3 h to let cells attach on the plates,
cells were changed to a new fresh medium containing 10% FBS/DMEM
to remove non-adherent cells. The remaining attached cells were
macrophages.Table 1
Treatment time on three individual groups.
Grp Treatment 1st 2nd 3rd
1 Acetone 11:40 am NA NA
2 Bethamethasone 11:50 am “ “
3 Extract 7:00 am 8:00 am 9:00 am2.3. TNFα inhibition activity assay
50 μg/ml of whole glucan particle beta-glucan (WGP) was added to
stimulate the recreation of inﬂammation factors. After 24 h of incubation
at 37 °C, 1 μl of the AO herbal extract was added to each well. After
another 24 h of incubation at the same temperature, the supernatants
were harvested and measured for the presence of the pro-inﬂammatory
cytokine TNFα. A commercial enzyme-linked immune-sorbent assay
(ELISA, Biolegend Inc) was used to detect the TNFα amount.
2.4. ELISA
An ELISA Max Deluxe Set Mouse TNFα kit (Biolegend) was used to
examine TNFα level in cultured supernatants. First, mouse TNFα ELISA
capture antibodywas diluted in 1× Coating buffer. 100 μl of this capture
solution was added to well and incubated overnight at 4 °C. Plate was
washed 4 times with 300 μl wash buffer (PBS+ 0.05% Tween-20) per
well, then 200 μl 1× Assay Diluent buffer (PBS + 10% FBS) was added
to block non-speciﬁc binding, shaken at room temperature for 1 h,
followed bywashing 4 timeswithwash buffer. After that, 100 μl of mac-
rophage supernatant was added to each well and incubated at room
temperature for 2 h with shaking, followed by washing plate 4 times
with wash buffer, and 100 μl of diluted detection antibody solution
was added to eachwell and incubated for 1 hwith shaking, thenwashed
4 times with wash buffer. 100 μl of diluted Avidin–HRP solution was
added to each well, incubating at room temperature for 30 min with
shaking, and washed 4 times with wash buffer. Finally, 100 μl of freshly
mixture substrate solution was added and incubated in the dark for
15 min with shaking, then stopped by adding 100 μl stop solution to
each well. The absorbance was read at 450 nm.
2.5. Inﬂammation stimulation on mice
12 female, 5- to 6-week-old BALB/c mice (Charles River Laborato-
ries) were housed in a two cages of three mice each and one cage
containing six mice. The mice were kept at routine maintenance and
shaved on the abdomen. 5% oxazolone solutionwas prepared by adding
250 mg 4-ethoxymethylene-2-phenyl-2-oxazolin-5-one (oxazolone,
MP Biomedicals, Inc.) to 5ml acetone (ACROS Organics) andwas stored
at 25 °C in the dark. To induce inﬂammation, 100 μl of 5% oxazolonewas
applied to the shaved portion of the abdomen of all mice.
2.6. In vivo mice inﬂammation inhibition assay
3% oxazolone solution was prepared by adding 150 mg oxazolone
to 5 ml acetone. The solution was stored at 25 °C in the dark.
Bethamethasone solution was prepared by 1.4 mg bethamethasone
17-valerate (Sigma) dissolved in 3.5 ml de-ionized water to yield a
0.4 mg/ml stock. 100 μl of this stock solution was diluted in 0.90 ml ac-
etone to prepare a 40 μg/ml preparation. Mice were divided into 3
groups. One group ofmice received a topical application of 25 μl acetone
to both sides of both ears (vehicle control). Another group of mice re-
ceived a topical application of 25 μl bethamethasone solution to both
sides of both ears (positive control). An hour later, 5 μl 3% oxazolone
was applied to both sides of the right ear; acetone was applied to both
sides of the left ear. The experimental group of mice received topical
applications of 10 μl extract to both sides of both ears (20 μl/ear) at
1 h intervals. 1 h after the sixth application, 5 μl 3% oxazolone was4th 5th 6th Oxazolone
NA NA NA 12:40 pm
“ “ “ 12:50 pm
10:00 am 11:00 am 12:00 pm 1:00 pm
Table 4
Effect of treatment on average change in earWeight (mg) (statistic of mouse ear weight).
Group Statistic Δ in Ear Wt
1 Mean 80.5
SD 5.8
2 Mean 25.7
SD 4.5
p-value 0.0002
3 Mean 45.4
SD 4.7
p-value 2 × 10−5
Table 2
Weight of each mouse ear.
Group Mouse Right Ear Left Ear
1 1 95.41 18.78
2 113.12 25.88
3 100.38 22.71
2 4 49.14 18.33
5 41.78 19.77
6 44.5 20.08
3 7 77.72 27.13
8 75.39 23.78
9 70.23 25.25
10 61.37 21.28
11 60.29 18.08
12 62.98 20.04
309H. Ye et al. / Experimental and Molecular Pathology 100 (2016) 307–311applied to both sides of the right ear, acetone was applied to both sides
of the left ear. Both ears were still damp from the last topical application
of extract.
2.7. Statistical analysis
Data are expressed as mean values ± SEM. Differences p ˂ 0.05.
3. Results
3.1. AO herbal extract inhibits TNFα activity on macrophage cells
AO herbal extract, obtained from Alpha Oasis LLC, was discovered to
have the ability to reduce inﬂammation for arthritis patients. To study
the inﬂammation mechanism, an animal model is needed. The mouse
model is the most efﬁcient system due to its ease of control, many in-
ﬂammation mechanisms were well characterized and had similarity to
humans. During the inﬂammation process, an orchestra of cytokines
are secreted in response to ﬁghting potential invasion by an outside in-
truder or internal repair of damage. Among these cytokines, pro-inﬂam-
matory factor TNFα was up-regulated and commonly used as the
marker of inﬂammation response.We ﬁrst examinedwhether AO herb-
al extract is able to inhibit the activity of mouse TNFα.
Resident peritoneal macrophages were obtained from 6- to 8-week-
old female mice. Themacrophages were screened in 24-well tissue cul-
ture plates at 0.2 × 106 cells per well. The cells were incubated at 37 °C
for 3 h to allow the cells to attach on the plates, then the cell medium
was changed to a new fresh medium containing 10% FBS/DMEM. To
stimulate the recreation of inﬂammation factors, 50 μg/ml of whole glu-
can particle beta-glucan (WGP)was added to eachwell. After 24 h of in-
cubation at the same temperature, 1 μl of the AO herbal extract was
added to the wells, followed by another 24 h of incubation at the
same temperature. Finally, the supernatant was harvested and mea-
sured for the presence of the pro-inﬂammatory cytokine TNFα. A com-
mercial enzyme-linked immunosorbent assay (ELISA, Biolegend Inc)
was used to detect the amount of TNFα. After WGP induction, theTable 3
Effect of treatment of each mouse on treated vs non-treated mice.
Group Mouse Δ in Ear Wt
1 1 76.63
2 87.24
3 77.67
2 4 30.81
5 22.01
6 24.42
3 7 50.59
8 51.61
9 44.98
10 40.09
11 42.21
12 42.94TNFα level was approximately 11,000 pg/ml (see Fig. 1, Left Lane). Sol-
vent DMSO was used as the negative control (right lane). In the well
containing AO (middle lane), the level of TNFα level decreased signiﬁ-
cantly, indicating that the AO extract is able to inhibit TNFα secretion
of macrophage cells.
3.2. AO herbal extract is able to inhibit inﬂammation on mouse ear
To further investigatewhether AOherbal extract is able to inhibit in-
ﬂammation at in vivo level, we take mouse ear edema model, a well-
established animal model for inﬂammation determination. This in vivo
model measures the effectiveness of topically administered materials.
Inﬂammation of the mouse ears is induced by application of oxazolone.
The herbal extract will be applied topically to the ears one day prior to
oxazolone-induced inﬂammation.
Twelve of 5- to 6-week-old female mice were used in this experi-
ment. All mice were ﬁrst injected with oxazolone in the abdomen to
induce the inﬂammation. After that, the mice were kept at room tem-
perature for a week at routine maintenance. A week later, the mice
were randomly divided into three groups. The vehicle control group re-
ceived a topical application of 25 μl actone to both ears. Positive control
group received a topical application of 25 μl bethamethasone solution to
both ears. An hour later, 5 μl 3% oxazolone was applied to the right ear
and acetone was applied to the left ear. The experimental group re-
ceived 20 μl to both ears at 1 h intervals (Table 1). 1 h after the sixth ap-
plication, 5 μl 3% oxazolone was applied to both sides of the right ear,
and acetone was applied to the left ear. To prevent the mice scratching
their ears during the process or lick their paws after the paw touches the
ear skin after scratching, Elizabethean collars were put on themice. 24 h
later, the mice were euthanized. Both ears were removed and weighed
(Table 2, Table 3). Statistical comparison of ear edemawill bemeasured
for the two groups (Table 4) andwill be used to assess the efﬁcacy of the
extract. In response to topical application with 3% oxazolone to the ears
of immunizedmice, about 3.5-fold increases in ear weight were record-
ed 24 h later. The application of the AO herbal extract yielded in a signif-
icant 43.6% inhibition of in the oxazolone-induced ear edema (Table 5 &
Fig. 2).
4. Discussion
Herbal medicines have been used to help improve human health be-
fore recorded history. Countless evidence and rich literature in history
have documented the signiﬁcances. Medicinal herbal products have
especially been long acknowledged as an efﬁcient method for anti-
inﬂammation. Despite the rich documentation that has recorded herbal
medicine successfully treating many complicated diseases, withoutTable 5
Overall the inhibition activity to inﬂammation for AO
herbal extract and bethamthasone.
Group % Inhibition
2 68.0
3 43.6
Fig. 2. Effect of prophylactic topical treatment with extract on oxazalone-induced ear EDEMA.
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medicine was largely hampered (Tian, 2011; Xu, 2011; Zhang et al.,
2012). Limited research tools and under-developed methods in the
past have restrained the development of herbal medicine treatment.
As we know now, one of the most efﬁcient methods of performing
mechanistic studies on a drug is to ﬁnd a compatible animal model
(Bockamp et al., 2002; Agrawal et al., 2007; Lossi et al., 2015). Here
we established the mouse model for AO herbal extract to investigate
its function on anti-inﬂammation activates. We have not only con-
ﬁrmed that the AO herbal extract is able to reduce inﬂammation by
in vivo and in vitro experiment but also established the mouse model
and assays for the further drug discovery studies.
Inﬂammation is a complex process that is coordinated by cytokines
and immune signaling molecules. The well-identiﬁed pathways for in-
ﬂammation are either activated by LPS, or by beta-glucan (Yan et al.,
1999; Steiner et al., 2005; Dantzer and Kelley, 2007; Li et al., 2007;Fig. 3. Schematic of beta-glucan stRummel et al., 2011). The assay we report here is stimulating macro-
phage cells by beta-glucan. Beta-glucan recognition was involved in
several receptors, and dectin is the most characterized with molecule
details. Dectin is a transmembrane receptor, containing an extracellular
domain, a single-transmembrane domain, and a short intracellular tail
(Fig. 3). The extracellular region of receptor binds to carbohydrate poly-
mer, with a variety of afﬁnity range from very low (3 × 10−3 M) to very
high (2 × 10−12 M), due to different sizes and where of branches of
beta-glucan from various sources (Fang et al., 2012; Kerscher et al.,
2013; Lee and Kim, 2014. After beta-glucan was recognized by Dectin,
the intracellular tail, which is responsible for transducing signals, re-
cruits kinases src and sky and its phosphorylation is the key to initiate
signaling. Another feature for intracellular signaling is the activation of
NFκB transcription factor by the adapter protein caspase recruitment
domain family member 9 (CARD9) and its interacting partners BCL10
and Malt1. After activation, NFκB translocated to nucleus and activeimulation signaling pathway.
311H. Ye et al. / Experimental and Molecular Pathology 100 (2016) 307–311various downstream transcription factors, and many inﬂammation-re-
lated proteins are synthesized, including TNFα (Brown, 2006; Saijo
and Iwakura, 2011; Yang et al., 2011).
In our experiments, after adding AO herbal extract, TNFα level re-
duced. There are a few possibilities: 1. The active compound in AO herb-
al extract is able to interfere with the interaction between beta-glucan
and its receptor dectin, therefore inhibiting downstream activation. 2.
The active compound enters the plasma membrane and interacts with
one or more downstream proteins and blocks the TNFα from releasing.
To clarify the possibility, more experiments are needed, including iden-
tifying the essential single compounds which have the maximal ability
to reduce TNFα secretion. However, this single compound might not
have the same level of efﬁcacy as the multiple components together.
Nevertheless, our studies here have now provided a framework for fur-
ther researching anti-inﬂammation compounds through inhibiting
TNFα signaling. Although we have established the animal model,
many more studies are required to ﬁnd efﬁcient drugs for anti-
inﬂammation—the important mechanism for many related diseases,
undoubtedly with surprises awaiting.
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